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Abstract: Significant progress has been made in pediatric kidney transplantation. Advances in immunosuppression have 
dramatically decreased rates of acute rejection leading to improved short term graft survival but similar improvements in 
long term graft survival remain elusive. Changes in allocation policy provide the pediatric population with timely access 
to transplant but there remains concern about the impact of less HLA matching and a decrease in living donors. This 
report presents data from North America on these successes and the ongoing challenges that face the pediatric transplant 
community. 
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INTRODUCTION 
 Kidney transplant is the goal of treatment for children 
with end stage renal disease. There has been significant 
progress made in the field of kidney transplant including 
immunosuppressive drug therapy, graft, and patient survival. 
This progress can be attributed to advances in numerous 
factors including pre-transplant care, surgical advances, 
changes in deceased donor allocation policy, and more 
potent immunosuppressive medications [1]. We present data 
from North America on these successes and the ongoing 
challenges that face the pediatric transplant community. Data 
sources such as the North American Pediatric Renal Trials 
and Cooperative Studies (NAPRTCS) transplant registry [2] 
and the Scientific Registry of Transplant Recipients (SRTR) 
[3] are valuable sources of data that allow trends in graft and 
patient outcomes in pediatric kidney transplant to be 
followed. Other registries include the Canadian Organ 
replacement Registry, the Latin American Pediatric Renal 
Transplant Cooperative Study and the ERA-EDTA 
(European Renal Association and European Dialysis and 
Transplantation Association) Registry. 
PATIENT CHARACTERISTICS 
 Characteristics of pediatric transplant recipients have 
remained similar over the past decade (Table 1). The most 
common age at transplant remains 11-17 years (58.8%), 
followed by 1-5-years (22.9%), 6-10 years (18.27%) and < 1 
year (0.1%) (2). Males account for approximately 60% of 
pediatric kidney transplant recipients.. The most common 
primary diagnosis of end stage renal disease is structural 
abnormalities (31.8%), focal segmental glomerulosclerosis 
(FSGS) (12.5%), and glomerulonephritis (10.8%). 
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 One demographic characteristic that is changing is the 
racial distribution of pediatric renal transplant recipients. The 
proportion of recipients who are Hispanic increased from 
19.5% in the 2000-2002 cohort to 27.1% in the 2010-2012 
cohort, which is reflective of changes in the general 
population. The etiology of end stage renal disease varies by 
ethnicity. FSGS is the leading cause among black transplant 
recipients, while structural causes (obstructive uropathy, 
dysplasia) are the most common among white and Hispanic 
transplant recipients. Awareness of these changes in 
recipient demographics is important to guide studies of 
outcomes in emerging populations. 
DECEASED DONOR ALLOCATION POLICY 
 Children are recognized as deserving priority in kidney 
allocation. Candidates who are listed before their eighteenth 
birthdays retain their pediatric priority until they are 
transplanted or removed from the waiting list. A Pediatric 
Advisory Committee was established by the OPTN in 1993. 
This group developed a white paper which presented the 
negative impact of ESRD and dialysis on the growth and 
development of pediatric patients. 
 In 2000, the Children’s Health Act was passed by 
Congress and incorporated as an amendment to National 
Organ Transplantation Act (NOTA). This Act states that 
organ allocation policy is to recognize the differences in 
health and organ transplant issues between children and 
adults throughout the system, and adopt criteria, policies, 
and procedures that address the unique health care needs of 
children. In September 2005, the United Network for Organ 
Sharing (UNOS) revised kidney allocation policy such that 
kidney allografts from deceased donors < 35 years were to 
be offered preferentially to pediatric patients (< 18 years 
old); Share 35. In June 2012, the Organ Procurement and 
Transplantation Network approved a new national deceased 
donor kidney allocation policy that goes into place in 
December 2014. The major goals of the new allocation 
policy are to decrease disparities in transplant access and to 
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align expected survival of the allograft with the expected 
survival of the recipient. This system will allocate the top 
20% of kidneys in the kidney donor profile index (KDPI) to 
candidates in the top 20% of expected post-transplant 
survival (EPTS) [4]. 
TRANSPLANT CHARACTERISTICS 
 The number of pediatric kidney transplants has remained 
steady between 750 and 800 over the past several years 
following a peak of 899 in 2005 (Fig. 1). There has been a 
decline in the proportion of pediatric patients receiving a 
living donor transplant and an increase in those receiving a 
deceased donor transplant. Living donor kidney transplants 
in pediatrics peaked in 2001 at 61% and has subsequently 
declined to 38% in 2013 [3]. This shift in donor source has 
also been seen in the adult kidney transplant population. In 
the pediatric population, there is concern that allocation 
policy may play a role. Review of data since Share 35 indeed 
reveals an increase in the number of transplants from 
deceased donors < 35 years among pediatric recipients. 
However, there was also a significant decrease in the 
proportion of transplants from living donors; 0.55 pre-Share 
35 to 0.35 post-Share 35 [5]. 
 Looking at the type of living donor, donation from 
related living donors has decreased over time, while 
donation from other living donors increased, possibly 
reflecting an increase awareness and willingness of 
community members (friends, teachers, church members) to 
donate (Fig. 2). By age, young recipients are the most likely 
to receive a living donor transplant The age of deceased 
donor organs allocated to pediatric transplant recipients has 
changed over time due to changes in allocation policy and 
clinical practice patterns (Fig. 3). Since Share 35, there has 
been an increase in the number of young deceased donor 
kidney transplants (< 35 yrs) from 62.8 to 133 per quarter (p 
< 0.001) with a decrease in the number of deceased donors 
> 35 years old from 22.4 to 2.6 per quarter (p < 0.001) [5]. In 
addition, the use of young donors has decreased over time 
with fewer that 10% of deceased donors being younger than 
5 years. 
 
Fig. (1). Donor source (SRTR Annual data report 2013). 
 Interestingly, despite being less common, recent 
NAPRTCS data revealed that kidneys from donors < 5 
years had equivalent patient and graft survival to those from 
donors > 5years [6]. Compared to the adult population, 
donation following circulatory death (DCD) kidneys were 




All Deceased Living All Deceased Living 
N % N % N % N % N % N % 
Age 
<1 13 0.6 0 0.0 13 1.1 3 0.1 2 0.1  0.1 
1-5 400 18.8 128 14.3 272 22.1 518 22.9 269 19.4 249 28.6 
6-10 424 20.0 181 20.2 243 19.8 412 18.2 248 17.8 164 18.8 
11-17 1,286 60.6 586 65.5 700 57.0 1,329 58.8 871 62.7 458 52.5 
Sex 
Female 866 40.8 381 42.6 485 39.5 907 40.1 578 41.6 329 37.7 
Male 1,257 59.2 514 57.4 743 60.5 1,355 59.9 812 58.4 543 62.3 
Race 
White 1,230 57.9 393 43.9 837 68.2 1'110 49.1 535 38.5 575 65.9 
Black 390 18.4 241 26.9 149 12.1 404 17.9 325 23.4 79 9.1 
Hispanic 414 19.5 214 23.9 200 16.3 613 27.1 449 32.3 164 18.8 
Asian 65 3.1 31 3.5 34 2.8 96 4.2 59 4.2 37 4.2 
Other/unk. 24 1.1 16 1.8 8 0.7 39 1.7 22 1.6 17 1.9 
Primary  
cause of  
disease 
FSGS 226 10.6 122 13.6 104 8.5 283 12.5 202 14.5 81 9.3 
GN 389 18.3 169 18.9 220 17.9 244 10.8 163 11.7 81 9.3 
Structural 746 35.1 304 34.0 442 36.0 719 31.8 424 30.5 295 33.8 
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infrequently used in pediatric kidney transplants recipients 
(< 5% vs 14.4%) [3]. Extended criteria donor kidneys are 
rarely used in pediatric recipients with only 1 case reported 
since 2007. 
 Over the past 25 years, twenty-four percent of primary 
transplants in the NAPRTCS transplant registry were 
preemptive; transplant without history of dialysis [2]. 
Preemptive transplant occurs more commonly among LD 
recipients (34%) compared to DD recipients (13%), more 
commonly in males (28%) than females (20%). The most 
common age of preemptive transplant recipients is 6-12 
years (28%). White transplant recipients are more likely to 
receive a preemptive transplant (31%) than Hispanic (16%) 
or black (13%) recipients. 
 The number of HLA mismatches has increased over time. 
In 2012, 85% of deceased donor kidney transplant recipients 
had > 3 HLA mismatches compared to 19.5% of living 
donor recipients (Fig. 4). Zero-HLA mismatched transplants 
have been less common after 2005 [7]. 
 
Fig. (3). Deceased donor age (SRTR Annual Data Report, 2013). 
 
 
Fig. (2). Living donor source (SRTR Annual Data Report, 2013). 
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 Over the past decade, between 12-20% of pediatric 
kidney transplant candidates were waiting for a re-transplant 
[3]. The challenge of this population is their high level of 
sensitization and the difficulty finding a suitable donor and 
the resulting long wait times. Various strategies to address 
this population have emerged including paired exchange 
programs and desensitization. In addition, the new kidney 
allocation policy gives a sliding scale of extra points for the 
degree of sensitization [4]. 
GRAFT SURVIVAL 
 Graft survival among pediatric kidney transplant 
recipients has improved significantly over the past decade 
[1] (Fig. 5). Recent analysis of US data demonstrated a 
dramatic improvement in death censored graft survival over 
the past 25 years; 1-year graft survival of 97.0% for 
transplants performed in 2010 compared with 80.9% in 
1987, 5-years graft survival of 77.9% for transplants 
performed in 2006 compared with 59.0% in 1987, and 10-
years graft survival of 60.2% for transplants performed in 
2001 compared with 46.8% in 1987. The median graft 
survival improved from 7.2 years for transplants performed 
in 1987 to 12.3 years for transplants performed in 1998 [7]. 
The leading cause of graft loss is chronic allograft 
nephropathy (35.3%) followed by acute rejection (13.2%), 
thrombosis (9.8%), and recurrence of original disease (7.0%) 
[2]. 
PATIENT SURVIVAL 
 Patient survival rates for living donor recipients were 
98.4%, 97.7%, 96.1%, 94.2%, and 92.4% at years 1, 2, 5, 7 
and 10 years post-transplant, respectively. Among deceased 
donor recipients, patient survival rates were 97.4%, 96.5%, 
93.3%, 91.1%, and 86.6% at years 1, 2, 5, 7, and 10 years 
post-transplant. Over the past decade, patient survival has 
significantly improved for both living donor (LD) and 
deceased donor (DD) recipients (Fig. 6). The difference 
between LD and DD survival rates has also decreased. 
 The causes of death have remained stable over time [2]. 
The leading cause of death among pediatric kidney 
transplant recipients is infection (28.5%), followed by 
cardiopulmonary (14.7%), malignancy (11.3%), and dialysis 
related complications (3.1%) [1]. Almost half of these 
patients died with a functioning graft. 
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Fig. (6). Patient survival (1). 
IMMUNOSUPPRESSION 
 There have been significant changes in the 
immunosuppressive therapy used in pediatric kidney 
transplantation which mirror the changes seen in the adult 
population (Fig.  7a, b). Looking at induction medication use 
in 2009, 54.6% of recipients did not receive induction 
immunosuppression, the highest level reported since 1996. 
The most common induction therapy was T cell depleting 
antibody (22.4%), which has increased in use in the last 3 
years. In contrast, use of IL-2 receptor antagonist decreased 
to 19.5%. Looking at maintenance immunosuppression, the 
use of cyclosporine has been virtually eliminated with the 
increased use of tacrolimus from 3.7% in 1996 to 62.1% in 
2009. Mycophenolate mofetil (MMF) use increased from 
9.0% in 1996 to 59.6% in 2009. Azathioprine use has 
decreased from 49.3% in 1996 to 2.5% in 2009. Sirolimus 
was introduced in 1998 with its use peaking in 2002 (25.5%) 
and subsequently decreasing to only 0.5% in 2009. Steroid 
avoidance and minimization protocols have become more 
common with only 48.8% of patients at day 30 receiving 
steroid treatment in 2009. The most commonly used drug 
combination for the transplant era 2003-2010 at day 30 post-
transplant was tacrolimus, MMF, prednisone in 56% of 
patients followed by tacrolimus and MMF in 14.8% of 
patients. 
REJECTION 
 Advances in immunosuppression have led to remarkable 
decreases in acute rejection rates (Fig. 5). NAPRTCS 
transplant registry data reveal that the acute rejection rate at 
1 year decreased in living donor recipients from 54% in the 
late 1980s to 8% most recently and among deceased donor 
recipients; from 69% to 17% [2]. 
 Late acute rejection occurring > 6 month post-transplant 
has been associated with poor long term graft survival [8]. 
Delayed graft function and de novo donor specific antibodies 
have been identified as risk factors. 
 Age is key determinant of acute rejection risk. The 
highest risk is in the adolescent recipient (> 12 year old) and 
the lowest risk is among recipients aged 0-1 years. Analysis 
of the impact of specific patient and transplant characteristics 
on the occurrence of first rejection episodes in patients 
transplanted from 1996 to 2010 demonstrate that among LD 
recipients, age < 24 months at transplant was associated with 
a decreased risk of rejection [2]. 
 Among deceased donor recipients, black recipient race 
was associated with an increased risk of rejection. Delayed 
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graft function (dialysis in the first week post-transplant) was 
associated with an increased risk of rejection in both living 
and deceased donor donor transplants. 
RENAL FUNCTION 
 The short-term renal function, measured by estimated 
glomerular filtration rate (eGFR), has improved in the 
pediatric kidney transplant population (Fig. 8). The 
proportions of patients with eGFR > 90 mL/min/1.73 m2 at 
discharge from transplant hospitalization increased from 
17.1% in 2000 to 34.6% in 2012, at 6 months post-transplant 
from 10.3% in 2000 to 26.3% in 2012, and at 1 year post-
transplant from 6.7% in 2000 to 25.9% in 2011 [3]. Among 
patients transplanted in 2011, 71% and 72% had CKD stage 
1-2 at 6 and 12 months post-transplant, respectively. 
Younger recipients begin with a higher eGFR post- 
transplant and are subject to greater absolute declines over 
time compared with older recipients (Fig. 9a, b). These 
differences in function by age at transplant become 
negligible over time in long-term renal allograft survivors, 
with the exception of the youngest (0-1 years) recipients who 
continue to have better function at 7 years post-transplant 
[2]. 
GROWTH 
 Optimizing growth and development is one of the key 
drivers of timely transplant. Data from the past 2 decades 
reveal that pediatric patients have significantly improved 
height Z scores at time of transplant from a mean deficit of 
2.43 in 1987 to 1.23 in 2009 [9]. 
 The mean height deficit for patients at the time of 
transplant was 1.75 standard deviations below the age- and 
sex-adjusted height level (Fig. 10). This deficit is greater for 
males (-1.78) than females (-1.70). Younger patients (2-
5 years) and re-transplant patients have greater height 
deficits. Growth hormone post-transplant resulted in a delta 
Z score of +0.5 standard deviations [9]. Patients < 6 years 
are the population who demonstrate the most accelerated 
growth post-transplant. Steroid avoidance protocols have 
been associated with improved post- transplant growth. 
 
Fig. (8). eGFR post transplant (SRTR Annual Data Report, 2013). 
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Patterns of weight gain post-transplant and the impact 
of steroid use has been studied in the pediatric population 
[10]. Analysis of NAPRTCS data revealed an increase in 
median BMI% of 11.4 units in the first six months post-
transplant. BMI% at time of transplant did not impact change 
in BMI% post-transplant. Steroid free immunosuppression 
was associated with smaller increases in BMI% than daily 
steroid based immunosuppression. 
 
Fig. (9a). Creatinine clearance (mean+-SE) by age among living 
donors. 
VIRAL COMPLICATIONS 
 The more potent immunosuppressive therapy that has 
successfully reduced the incidence of acute rejection and 
improved graft outcomes has also resulted in a higher 
incidence of viral complications [11]. Infections have now 
replaced rejection as the leading cause of hospitalization in 
the pediatric kidney transplant population [12]. Significant  
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morbidity, graft loss, and mortality are attributable to viruses 
such as BKV, Epstein Barr virus (EBV), and 
cytomegalovirus (CMV). Pediatric kidney transplant 
recipients represent a unique and and at risk population due 
to their increased risk for primary infection. 
MALIGNANCY 
 Since the mid-1990s, the incidence of the Epstein Barr 
virus (EBV)-associated cancer known as post-transplant 
lymphoproliferative disorder (PTLD) has dramatically 
increased [1]. In addition, solid tumors have been reported in 
the pediatric kidney transplant population [13]. 
CONCLUSION 
 Significant progress has been made in pediatric kidney 
transplant outcomes. Advances in immunosuppression have 
dramatically decreased acute rejection rates and improved 
short term graft survival, but infectious complications have 
emerged as a significant source of morbidity and mortality. 
Changes in allocation policy provide the pediatric population 
with timely access to transplant, but there remains concern 
about the impact of less HLA matching and a decrease in 
living donors. The remaining challenge for the transplant 
community is to improve long term graft survival by 
optimizing access to timely transplant while maintaining 
donor quality and tailoring immunosuppression which 
minimizes complications. 
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